Sold as Zanosar. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Streptozocin (sold as Zanosar), first approved May 7, 1982, with 0 new uses approved and 0 published complete response letters.
| Effect of Melatonin in Patients With Diabetic Peripheral NeuropathyDiabetic Peripheral Neuropathy, Diabetic Neuropathy · Ain Shams University | Phase 2 | Recruiting | Jun 25, 2025 |
| An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With HyperkalaemiaHyperkalaemia · AstraZeneca | Phase 3 | Recruiting | Jan 23, 2019 |
| Two Chemotherapy Regimens Plus or Minus BevacizumabPancreatic Cancer · Gustave Roussy, Cancer Campus, Grand Paris | Phase 2 | Active, not recruiting | Nov 22, 2017 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| May 7, 1982 | ZanosarNDA 50577 · New molecular entity | Teva Pharms USA | 21 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA